Top

HPTN 084

Projects

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women 

Rationale

PrEP may only reach its full potential for HIV prevention with agents that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.

Investigators

  • Dr Carrie-Anne Mathew (Co-Principal Investigator)
  • Dr Elizabeth Roos (Co-Principal Investigator)
  • Prof Sinead Delany-Moretlwe (Sub Investigators)
  • Dr Monique Da Fonseca (Sub Investigators)
  • Dr Juliet Vimbai Rundogo (Sub Investigators)
  • Dr Nicole Poovan (Sub Investigators)

Latest Update

April 2024

For more details about HPTN 084 please email rhicomms@wrhi.ac.za

Click here for further details regarding the HPTN 084 study.

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.